Orthogonal comparison with established Simoa assays
NULISAseq and Simoa measurements were strongly correlated for NfL and GFAP, providing direct cross-platform evidence for those two analytes.
↳ Results, Fig. 3A–B
Abstract
Motor neuron disease (MND) presents with phenotypic heterogeneity, is diagnostically challenging, and has poor prognosis. The absence of accessible blood-based biomarkers has hampered progress towards precision medicine. Highly sensitive immunoassays offer considerable promise for identifying blood-based biomarkers informing underlying pathophysiology and enabling accurate diagnosis and monitoring. We report findings on parallel use of the ultra-sensitive multiplexed NUcleic Acid-Linked Immuno-Sandwich Assay (NULISA) and single molecule array (Simoa), to interrogate serum from people with MND. Sera (48 MND, 38 controls) were analysed using a NULISAseq targeted neurodegenerative panel and a Simoa neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) duplex assay. Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05). Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90). Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND, and replicated findings for other proteins from recent studies. Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq, while offering insights into the underlying pathophysiology and heterogeneity of MND.
Key Claims
Primary findingSupported
Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05).
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
cross-sectional unadjusted comparisons limit disease specificity, especially for low-detectability pTau-217
Abstract; Results, Fig. 2A
SecondaryWell-supported
Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90).
reported Spearman correlations directly support the claim for both measured analytes
Abstract; Results, Fig. 3A–B
SecondaryTentative
Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq.
two-analyte cross-platform correlation cannot establish broader biomarker validity or reproducibility
Abstract; Conclusion
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Defined assay quality-control procedures
The workflow reports a randomized plate map, internal-control acceptance ranges, detectability thresholds, duplicate Simoa measurements, and a CV criterion.
↳ Methods, NULISAseq Profiling and Simoa sections
Direct engagement with recent literature
The discussion compares the serum findings with recent plasma and genetic-ALS NULISAseq studies and delineates the serum and broader-MND extensions.
↳ Discussion, paragraphs 2–4
Limitations
Primary comparisons lack confounding adjustment
Age and sex differed between disease and control groups, but biomarker comparisons used unadjusted independent t-tests without matching, regression, stratification, or sensitivity analysis.
↳ Methods, Statistical Analysis; Results, paragraphs 1–2; Discussion, limitations paragraph
Selected-sample analyses overstate discrimination
Clustering and ROC analyses were conducted in the discovery sample using the nine proteins selected as significant, without cross-validation or independent validation. This limits claims of clear separation, heterogeneity, and diagnostic performance.
↳ Results, Fig. 2B and Supplementary Fig. 9; Discussion, heatmap-analysis paragraph
Conclusions exceed the pilot evidence
The Conclusion invokes astrocytic degeneration, pathophysiological insight, and assay robustness although GFAP was unchanged and the study was a small, unadjusted cross-sectional pilot.
↳ Discussion, neuroinflammation and limitations paragraphs; Conclusion
Nabu Commentary
The serum panel identified nine FDR-significant proteins and reproduced the established NfL signal, while Fig. 3 provides direct cross-platform correlation evidence for NfL and GFAP. Methodological credit is limited by unadjusted t-tests despite documented age and sex differences between groups. The selected-feature clustering and in-sample ROC analysis do not independently establish diagnostic separation or MND heterogeneity. The paper is therefore best interpreted as an exploratory replication and assay-concordance study rather than clinical validation of a disease-specific panel.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Limited2.8
Confidence mediumContribution
3.2
The study adds an incremental serum-based replication across a mixed MND cohort and a two-analyte comparison with Simoa. Its advance remains limited because NfL elevation is established and several panel findings overlap recent NULISAseq studies.
Abstract; Discussion, paragraphs 2–4
Use of the multiplexed NULISAseq panel confirmed a well-established NfL elevation in MND
Methodological Rigour
2.4
Randomized plate allocation, assay QC, FDR correction, and duplicate Simoa measurements support the laboratory workflow. The primary comparisons remain unadjusted for documented age and sex differences, while control selection and in-sample feature evaluation add uncertainty.
Methods, NULISAseq Profiling and Statistical Analysis; Results, paragraphs 1–2 and Fig. 2
These exclusions affected the sex distribution difference between groups for the final analysis
Reporting
3.3
The manuscript follows a clear progression from hypotheses through multiplex testing and cross-platform comparison. Central claims about assay robustness, astrocytic degeneration, and heterogeneity are stronger than the unadjusted pilot and selected-feature clustering support.
Abstract; Discussion, heatmap-analysis paragraph; Conclusion
provide further confidence in the validity and robustness of the NULISAseq assay
Positioning
3.0
The discussion compares the findings with recent NULISAseq and broader biomarker studies and identifies the serum and mixed-MND extensions. Age and sex imbalance is acknowledged but not traced through the certainty of disease-specific biomarker interpretations.
Discussion, paragraphs 2–4 and limitations paragraph; Conclusion
differences between the age and sex of disease and control groups
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The reported numerical findings are largely coherent, but several interpretive statements are broader than the underlying pilot design and results support. These are interpretation watch-outs rather than evidence that the principal NfL result is unreliable.
Research ConductClean
Ethics approvals and informed consent are declared, and the article states that raw data are available on request and names code repositories. No conduct concern grounded in the supplied text was identified.
Flags: 3 declared / 5 total
Reference IntegrityClean
33 references in manuscript 33 of 33 checkable references found in an index
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 08 Oct 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
The work is an exploratory cross-sectional pilot rather than a prospective diagnostic or monitoring validation study. In-sample ROC performance and assay correlation do not establish readiness for clinical deployment.
Introduction, final paragraph; Results, ROC-analysis paragraph
in a cross-sectional pilot study
AI-generated, human-governed. Something look off? Contact us to request a review.